Findings based on virtual-reality traffic scenarios for people with and without age-related macular degeneration
WEDNESDAY, Jan. 7, 2026 (HealthDay News) — People with central vision loss can judge arrival time of approaching vehicles almost as accurately as people with normal vision, according to a study published online Dec. 4 in PLOS ONE.
Patricia R. DeLucia, from Rice University in Houston, and colleagues measured the contribution of visual and auditory cues during time-to-collision judgments made by people with age-related macular degeneration versus a control group without age-related macular degeneration, using a virtual reality system to simulate a roadway with an approaching vehicle viewed from the perspective of a pedestrian.
The researchers found that in the vision-only modality condition, the relative importance of distance and optical size compared with time-to-collision was higher in the impaired vision group versus the normal vision group, although the effect size was relatively small. For car presentation both visually and aurally, the mean absolute error of time-to-collision estimates was similar between groups, with no multimodal advantage seen. In the impaired vision group, intraindividual variability was greater only in the audio-visual condition.
“Our results indicate that even reduced central vision still provides useful information for judging approaching objects,” coauthor Daniel Oberfeld, from Johannes Gutenberg-Universität Mainz in Germany, said in a statement. “People with age-related macular degeneration continue to benefit from their residual vision instead of relying solely on auditory cues.”
Pooled Cohort Equations CV Risk Score Stratifies Risk for Ocular Disease
Handgrip Strength Inversely Linked to Age-Related Macular Degeneration
Risk for Motor Vehicle Crash Elevated After Concussion
AAO: PRIMA Implant and Glasses Improve Visual Acuity in Geographic Atrophy
Intravitreal Hydroxypropylmethylcellulose Improves Vision in Hypotony
AAO: Donor Diabetes Status Does Not Impact Success of Descemet Membrane Endothelial Keratoplasty
Revakinagene Taroretcel Reduces Ellipsoid Zone Area in Macular Telangiectasia Type 2